|
|
抗血管生成剂于晚期和复发性宫颈癌的临床研究
|
Abstract:
宫颈癌的发病率和死亡率在全球恶性肿瘤居第四位。宫颈癌的主要治疗方式包括手术及放化疗，晚期和复发性患者虽采用化疗为主的个体化治疗，但治疗效果的有限，病情迅速恶化并死亡。联合应用抗血管生成剂可阻止肿瘤进展，提高患者的生存期，为晚期和复发性宫颈癌的治疗提供新思路，本文将抗血管生成剂对宫颈癌的作用机制和相关临床试验进展作一综述。
Cervical cancer has the fourth highest incidence and mortality rate in the world for malignant tu-mors. The main treatment methods of cervical cancer include surgery and chemoradiotherapy, and although advanced and recurrent patients use chemotherapy-based individualized treatment, the treatment effect is limited, and the disease deteriorates rapidly and dies. The combined use of antiangiogenic agents can prevent tumor progression, improve the survival of patients, and provide new ideas for the treatment of advanced and recurrent cervical cancer. This article reviews the mechanism of action of antiangiogenic agents on cervical cancer and the progress of related clinical trials.
| [1] | 秦叔逵, 李进. 阿帕替尼治疗胃癌的临床应用专家共识[J]. 临床肿瘤学杂志, 2015, 20(9): 841-847. |
| [2] | 谢群星. 阿帕替尼联合替吉奥治疗老年晚期胃癌的近期疗效及其对患者免疫功能的影响[J]. 肿瘤基础与临床, 2020, 33(3): 231-233. |
| [3] | Guo, Q., Sun, Y., Kong, E., et al. (2020) Apatinib Combined with Chemotherapy or Concurrent Chemo-Brachytherapy in Patients with Recurrent or Advanced Cervical Cancer: A Phase 2, Randomized Controlled, Prospective Study. Medicine, 99, e19372. https://doi.org/10.1097/MD.0000000000019372 |
| [4] | 王琦琪, 信亚晨, 史尚雨宸, 等. 阿帕替尼联合调强放疗治疗老年中晚期宫颈癌的疗效及安全性分析[J]. 现代肿瘤医学, 2020, 28(18): 3211-3214. |
| [5] | 金燕芬, 沈威. 西地尼布抗肿瘤作用的临床研究进展[J]. 中国现代应用药学, 2017, 34(1): 143-146. |
| [6] | Symonds, R.P., Gourley, C., Davidson, S., et al. (2015) Cediranib Combined with Carboplatin and Paclitaxel in Patients with Metastatic or Recurrent Cervical Cancer (CIRCCa): A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial. The Lancet Oncology, 16, 1515-1524. https://doi.org/10.1016/S1470-2045(15)00220-X |
| [7] | Schutz, F.A.B., Choueiri, T.K. and Sternberg, C.N. (2011) Pazopanib: Clinical Development of a Potent Anti-Angiogenic Drug. Critical Reviews in Oncolo-gy/Hematology, 77, 163-171. https://doi.org/10.1016/j.critrevonc.2010.02.012 |
| [8] | Monk, B.J. and Pandite, L.N. (2011) Survival Data from a Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy in Patients with Ad-vanced and Recurrent Cervical Cancer. Journal of Clinical Oncology, 29, 4845-4845.
https://doi.org/10.1200/JCO.2011.38.8777 |
| [9] | Funakoshi, T., Latif, A. and Galsky, M.D. (2013) Risk of Hema-tologic Toxicities in Cancer Patients Treated with Sunitinib: A Systematic Review and Meta-Analysis. Cancer Treatment Reviews, 39, 818-830.
https://doi.org/10.1016/j.ctrv.2013.01.004 |
| [10] | Mackay, H.J., Tinker, A., Winquist, E., et al. (2010) A Phase II Study of Sunitinib in Patients with Locally Advanced or Metastatic Cervical Carcinoma: NCIC CTG Trial IND. 184. Gynecologic Oncology, 116, 163-167.
https://doi.org/10.1016/j.ygyno.2009.08.012 |
| [11] | Gao, Y., Liu, P. and Shi, R. (2020) Anlotinib as a Molecular Tar-geted Therapy for Tumors. Oncology Letters, 20, 1001-1014. https://doi.org/10.3892/ol.2020.11685 |
| [12] | Han, B., Li, K., Wang, Q., et al. (2018) Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients with Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncology, 4, 1569-1575. https://doi.org/10.1001/jamaoncol.2018.3039 |
| [13] | Chi, Y., Fang, Z., Hong, X., et al. (2018) Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma Anlotinib for Soft-Tissue Sarcoma. Clinical Cancer Research, 24, 5233-5238. https://doi.org/10.1158/1078-0432.CCR-17-3766 |
| [14] | 李姝. 新辅助化疗, 安罗替尼联用对宫颈癌组织中微血管密度表达的影响观察[J]. 医药界, 2020(4): 67-68. |
| [15] | 范仁亮. 安罗替尼联合紫杉醇加卡铂对晚期宫颈癌患者生存时间及睡眠质量的影响[J]. 世界睡眠医学杂志, 2020, 7(12): 2050-2052, 2021. |
| [16] | Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660 |
| [17] | 刘欣, 张国楠. 血清胆固醇水平对宫颈癌患者预后的影响[J]. 现代妇产科进展, 2021, 30(4): 255-258. |
| [18] | 庞留勇, 赵中, 李秋英. 宫颈癌放射治疗的数学模型研究[J]. 信阳师范学院学报 (自然科学版), 2022, 35(1): 1-6. |
| [19] | Lee, N., Kim, S.I., Lee, M., et al. (2019) Bevacizumab Efficacy and Re-currence Pattern of Persistent and Metastatic Cervical Cancer. In Vivo, 33, 863-868. https://doi.org/10.21873/invivo.11551 |
| [20] | Huang, Y., Goel, S., Duda, D.G., et al. (2013) Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy Vascular Normalization to Boost Immunotherapy. Cancer Research, 73, 2943-2948.
https://doi.org/10.1158/0008-5472.CAN-12-4354 |
| [21] | Multhoff, G. and Vaupel, P. (2020) Hypoxia Compromises Anti-Cancer Immune Response. In: Ryu, P.-D., La Manna, J.C., Harrison, D.K. and Lee, S.-S., Eds., Oxygen Transport to Tissue XLI, Springer, Berlin, 131-143.
https://doi.org/10.1007/978-3-030-34461-0_18 |
| [22] | Apte, R.S., Chen, D.S. and Ferrara, N. (2019) VEGF in Signaling and Disease: Beyond Discovery and Development. Cell, 176, 1248-1264. https://doi.org/10.1016/j.cell.2019.01.021 |
| [23] | Di Tacchio, M., Macas, J., Weissenberger, J., et al. (2019) Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. Cancer Immunology Research, 7, 1910-1927. https://doi.org/10.1158/2326-6066.CIR-18-0865 |
| [24] | 李国慧. 人类乳头状瘤病毒载量与宫颈病变关系研究进展[J]. 中国医药, 2013, 8(7): 1039-1040. |
| [25] | Pal, A. and Kundu, R. (2020) Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Frontiers in Microbiology, 10, 3116. https://doi.org/10.3389/fmicb.2019.03116 |
| [26] | Eskander, R.N. and Tewari, K.S. (2014) Targeting Angiogenesis in Advanced Cervical Cancer. Therapeutic Advances in Medical Oncology, 6, 280-292. https://doi.org/10.1177/1758834014543794 |
| [27] | 陈建华, 叶丽君, 喻长法, 等. 骨桥蛋白, 血管内皮生长因子和基质金属蛋白酶-9在宫颈癌患者中的表达及意义[J]. 中国卫生检验杂志, 2020, 30(18): 2215-2217. |
| [28] | Rossi, L., Verrico, M., Zaccarelli, E., et al. (2017) Bevacizumab in Ovarian Cancer: A Critical Review of Phase III Studies. Oncotarget, 8, 12389-12405. https://doi.org/10.18632/oncotarget.13310 |
| [29] | Chelariu-Raicu, A., Coleman, R.L. and Sood, A.K. (2019) Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient Is It Most Likely to Benefit? Oncology, 33, Article ID: 629378. |
| [30] | Garcia, J., Hurwitz, H.I., Sandler, A.B., et al. (2020) Bevacizumab (Avastin？) in Cancer Treatment: A Review of 15 Years of Clinical Experience and Future Outlook. Cancer Treatment Reviews, 86, Article ID: 102017.
https://doi.org/10.1016/j.ctrv.2020.102017 |
| [31] | Abu-Rustum, N.R., Yashar, C.M., Bean, S., et al. (2020) NCCN Guidelines Insights: Cervical Cancer, Version 1.2020: Featured Updates to the NCCN Guidelines. Journal of the Na-tional Comprehensive Cancer Network, 18, 660-666.
https://doi.org/10.6004/jnccn.2020.0027 |
| [32] | Tewari, K.S., Sill, M.W., Long III, H.J., et al. (2014) Improved Survival with Bevacizumab in Advanced Cervical Cancer. New England Journal of Medicine, 370, 734-743. https://doi.org/10.1056/NEJMoa1309748 |
| [33] | Gyawali, B. and Iddawela, M. (2017) Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries. Journal of Global Oncology, 3, 93-97. https://doi.org/10.1200/JGO.2016.004895 |
| [34] | 韩楠楠, 姜秋颖, 李里, 等. 重组人血管内皮抑制素(恩度)临床机制的研究进展[J]. 现代生物医学进展, 2019, 19(15): 2993-2995. |
| [35] | 许潇月, 沈波, 冯继锋. 重组人血管内皮抑制素的作用机制及其在肿瘤治疗中的研究进展[J]. 南京医科大学学报: 自然科学版, 2018, 38(8): 1167-1174. |
| [36] | Marko, R., Tanja, V. and Kukk-Valdre, E. (2001) Interaction of Endostatin with Integrins Implicated in Angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 98, 1024-1029.
https://doi.org/10.1073/pnas.98.3.1024 |
| [37] | 唐宇辰, 韦情虹, 徐晓颖. 重组人血管内皮抑制素对宫颈癌放疗增敏作用的研究[J]. 中国医师进修杂志, 2021, 44(1): 67-71. |
| [38] | Li, K., Shi, M. and Qin, S. (2018) Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment. Oncology and Therapy, 6, 21-43. https://doi.org/10.1007/s40487-017-0055-1 |
| [39] | 苗静, 秦叔逵. 重组人血管内皮抑制素治疗恶性胸腔积液的研究进展[J]. 临床肿瘤学杂志, 2019, 24(9): 850-855. |
| [40] | 罗菊玉. 重组人血管内皮抑制素辅助治疗中晚期宫颈癌效果观察[J]. 山东医药, 2016, 56(42): 72-74. |
| [41] | Zhang, K., Wang, H., Wang, Z., et al. (2020) Intensi-ty-Modulated Radiation Therapy (IMRT)-Based Concurrent Chemoradiotherapy (CCRT) with Endostar in Patients with Pelvic Locoregional Recurrence of Cervical Cancer: Results from a Hospital in the Qinghai-Tibet Plateau. Medicine, 99, e21966. https://doi.org/10.1097/MD.0000000000021966 |
| [42] | 谭柳, 楚阿兰, 杨瑜, 等. 安罗替尼联合化疗在子宫颈癌进展期患者中的疗效与安全性观察[J]. 实用妇产科杂志, 2022, 38(4): 305-309. |
| [43] | Tong, X., Wang, F., Liang, S., et al. (2012) Apatinib (YN968D1) Enhances the Efficacy of Conventional Chemotherapeutical Drugs in Side Population Cells and ABCB1-Overexpressing Leukemia Cells. Biochemical Pharmacology, 83, 586-597. https://doi.org/10.1016/j.bcp.2011.12.007 |
